Technology
Phylloceuticals’ scientists are world leading experts in genetically modified plants to produce proteins for therapeutics. The company offers two complementary bio-production which offer advantages across a spectrum of human therapeutic proteins:
These growth formats offer advantages for different production needs:
1. Vertical – Transient genetically modified tobacco bioproduction format – can produce kgs / week within 3 weeks notice
- Ideal for providing immediate production of urgently needed vaccine antigens and antibodies (pandemic needs), eliminating the long wait period for bioproduction
2. Aquaculture - Lemna bioproduction format
- Genetic stability of transgenes in Lemna enables consistent recombinant protein expression over years of production
- Lemna has the fastest, clonal growth of any bioproduction platform highly suitable for large scale production with simple, low-cost growth conditions.
- Stable genetically modified Lemna is ideal for lower cost, larger scale continuous production for biomolecules.
PHYLLOCEUTICALS brings these platforms together in one offering
- Plant Made Pharmaceuticals (PMP)
- Phytopharma as a Sustainable Technology (PhAAST™)
Biologics and vaccines can now be rapidly manufactured and delivered locally by regionally employing the PMP platform. Plants grow quickly and can be transfected to produce required human therapeutics without the capital expense of traditional stainless steel bioreactor infrastructure.
Over the last 30 years, advancements in recombinant technologies have been used to produce therapeutic biologic molecules, i.e. antibodies, vaccines, peptides, and others. The PMP sector has grown too, and many biologics and vaccines have emerged in the PMP space.
The 2020 pandemic focused the world on food security and pharmaceutical security. Every country is evaluating ways to manufacture and supply their citizens with needed medicines. Phylloceuticals is keenly aware of this dynamic and is focused on providing underserved markets in the US and globally. The PhAAST™ technology provides a rapid manufacturing platform to address cancer, infectious disease, and chronic disease.
Our response to these opportunities is to provide Phytopharma As A Sustainable Technology (PhAAST™) to global customers in both developed and developing regions.
The key features of PhAAST™ are:
- Lower cost facilities and operations
- Continuous improvements in plant-made pharmaceutical manufacturing systems
- Rapid process and product development of new pharmaceutical candidates
- Continuously optimized product vectors for an expanding product pipeline and increased production yield.
- Management and staff recruitment and training
- Automation, manufacturing data security, and AI-based process management brings the “Next-Gen”, plant-made pharmaceutical manufacturing platform to global centers.
- Global regulatory strategy support and clinical trial structure and management
- Definition of geographic regions for marketing products, with a special emphasis on bringing biologics manufacturing security to under served markets
- Assistance with obtaining capital
